Ken Griffin Design Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,100 shares of DSGN stock, worth $6,534. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,100
Previous 100
1000.0%
Holding current value
$6,534
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding DSGN
# of Institutions
101Shares Held
31.5MCall Options Held
1.1KPut Options Held
21.3K-
Sr One Capital Management, LP6.53MShares$38.8 Million9.6% of portfolio
-
Logos Global Management LP San Francisco, CA5.03MShares$29.9 Million1.58% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$13.7 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY1.7MShares$10.1 Million0.08% of portfolio
-
Tang Capital Management LLC San Diego, CA1.48MShares$8.8 Million0.61% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $331M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...